Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAD 600 for Prevention of Myocardial Injury in Pneumonia
2023-503950-11-00Phase 3Authorised
- Sponsor
- Biomedica Foscama S.p.A.
- Start
- Feb 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Myocardial injury and pneumonia comparing TAD (glutathione) arm with Placebo arm (2 arms). Primary endpoint: Change in high-sensitivity cardiac troponin (hs-cTn) from baseline (V0) to V1. Planned start Feb 2024; status: authorised.
02
Drugs
thioguanine + cytarabine + daunorubicin
03
Conditions
Myocardial injurypneumonia
Beyond the preview
Go deeper on 2023-503950-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503950-11-00.